LGC Limited   Report issue

For profit Phase 1 Phase 2
Founded: Teddington United Kingdom (1996)

Organization Overview

First Clinical Trial
2015
NCT02912949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

LGC Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

ensifentrine (1 trial)

mcla-128 (1 trial)

Drugs in Phase 1 Trials (1)

mcla-117 (1 trial)

Drugs in Other Trials (1)

cow milk (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4